Mail & Guardian
Mail & Guardian
Wits RHIIn the news

Two scholars honoured with Lifetime Achievement Award at 2026 NRF Awards

The Lifetime Achievement Award at the 2026 National Research Foundation (NRF) Awards went to two extraordinary and veteran scholars, Professor Jonathan Jansen and Professor Helen…

Video

SA and Zambia’s HIV shot dilemma: Demand versus supply

South Africa and Zambia are grappling with a significant challenge in rolling out lenacapavir, a new six-monthly HIV prevention injection. Despite high demand and promising early…

#Aids2026: Bhekisisa analysed SA’s first LEN roll-out data. Here's what it found

South Africa accounts for over half of all lenacapavir (LEN) users in Africa, with health department data revealing 31,297 of the continent's roughly 60,000 users are in the…

#Aids2026: Daily pill. Monthly pill. Six-monthly jab. Why choice matters

For the first time, Merck has granted generic manufacturers, including three African companies, permission to produce an investigational monthly HIV prevention pill, alimatravir,…

Ebola is back. So are the double standards

Just four years after COVID-19, the US is demanding an Ebola quarantine camp in Kenya, while Western countries impose travel bans on African nations. This article explores the…